Skip to main content
  •   Home
  •   Download
  •   Manual
  •   Contact

Drug Details

General Information of the Drug (ID: DR3524)
Name
Lithium chloride
Synonyms
LITHIUM CHLORIDE; 7447-41-8; Lithium chloride (LiCl); Lithiumchloride; LiCl; chlorolithium; chlorure de lithium; MFCD00011078; Lithium Cholride; UNII-G4962QA067; CHEBI:48607; CHEMBL69710; Chlorku litu; NSC327172; G4962QA067; Lithiumchlorid; Lithium Chloride, Anhydrous; Lithium chloride, ultra dry; Chlorku litu [Polish]; Lithium chloride, 99%, extra pure; Luthium chloride; ClLi; Lithium chloride, 99+%, ACS reagent; Chlorure de lithium [French]; CCRIS 5924; Lithium chloride, 99%, for molecular biology; HSDB 4281; Lithium chloride, 99%, for analysis, anhydrous; Lithium chloride solution; EINECS 231-212-3; lithium(1+) ion chloride; NSC 327172; Lithium Chloride (2.3% in Tetrahydrofuran, ca. 0.5mol/L); lithim chloride; lithii chloridum; lithium;chloride; Lithium chloride, anhydrous, chunks, 99.99% trace metals basis; cloruro de litio; Lithium Chloride Salt; Lopac-L-4408; Lithium chloride (powder); MolMap_000071; WLN: LI G; EC 231-212-3; LithiumChlorideGr(Anhydrous); Lithium chloride, ACS grade; Lopac0_000604; Lithium chloride battery grade; Lithium chloride 1 M solution; Lithium chloride, ACS reagent; DTXSID2025509; Lithium chloride, 3-5% in THF; HMS3261J10; Tox21_500604; ANW-36491; BDBM50494542; AKOS015902822; AKOS015950647; AKOS024438070; Lithium chloride, 1M aqueous solution; CCG-204693; lithium chloride, gamma irradiated, 8m; LP00604; NSC-327172; SDCCGSBI-0050586.P002; Lithium chloride, ACS reagent, >=99%; Lithium chloride, ReagentPlus(R), 99%; NCGC00015607-01; NCGC00015607-02; NCGC00015607-03; NCGC00015607-04; NCGC00015607-07; NCGC00093980-01; NCGC00093980-02; NCGC00261289-01; AK323906; BP-13612; Lithium chloride, 200mM aqueous solution; SY002997; Lithium chloride solution, 1 M in ethanol; Lithium chloride solution, 2 M in ethanol; Lithium chloride, Vetec(TM) reagent grade; EU-0100604; FT-0627896; L0204; L0222; Lithium chloride, Trace metals grade 99.9%; W8215; L 4408; Lithium chloride, SAJ first grade, >=98.0%; Lithium chloride, for molecular biology, >=99%; Lithium chloride, SAJ special grade, >=99.0%; A838146; Lithium chloride, BioXtra, >=99.0% (titration); Q422930; SR-01000076252; SR-01000076252-1; Electrolyte solution, nonaqueous, 2 M LiCl in ethanol; Lithium chloride solution, 1 M in glacial acetic acid; Lithium chloride, powder, >=99.99% trace metals basis; Z1741960146; Electrolyte solution, nonaqueous, LiCl in ethanol (saturated); Lithium chloride solution, 0.5 M in anhydrous tetrahydrofuran; Lithium chloride solution, 8 M, for molecular biology, >=99%; Lithium chloride, puriss. p.a., anhydrous, >=99.0% (AT); Lithium chloride solution, 1 M in 1,3-dimethyl-2-imidazolidinone; Lithium chloride, anhydrous, beads, -10 mesh, >=99.9% trace metals basis; Lithium chloride, anhydrous, beads, -10 mesh, 99.998% trace metals basis; Lithium chloride, puriss. p.a., ACS reagent, anhydrous, >=99.0% (AT); Lithium chloride, anhydrous, free-flowing, Redi-Dri(TM), ACS reagent, >=99%; Lithium chloride, anhydrous, free-flowing, Redi-Dri(TM), ReagentPlus(R), 99%; Lithium chloride, BioUltra, for molecular biology, anhydrous, >=99.0% (AT); Lithium atomic spectroscopy standard concentrate 1.00 g Li, 1.00 g/L, for 1 l standard solution, analytical standard; Lithium standard solution, suitable for atomic absorption spectrometry, 1 mg/mL Li, 1000 ppm Li
    Click to Show/Hide
Molecular Type
Small molecule
Disease Multiple myeloma [ICD-11: 2A83] Investigative [1]
Structure
Click to Download Mol
2D MOL

3D MOL

    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
ClLi
PubChem CID
433294
Canonical SMILES
[Li+].[Cl-]
InChI
1S/ClH.Li/h1H;/q;+1/p-1
InChIKey
KWGKDLIKAYFUFQ-UHFFFAOYSA-M
CAS Number
CAS 7447-41-8
ChEBI ID
CHEBI:48607
TTD Drug ID
D07WXT
DrugBank ID
DB16607
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug
          Arsenic trioxide      Realgar and orpiment     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    Molecule(s)
                    Regulation
Down-regulation Expression Gli1  Molecule Info 
Pathway MAP
Up-regulation Phosphorylation GSK-3B  Molecule Info 
Pathway MAP
                    In-vitro Model RD CVCL_1649 Embryonal rhabdomyosarcoma Homo sapiens
Rh30 CVCL_0041 Alveolar rhabdomyosarcoma Homo sapiens
                    Experimental
                    Result(s)
Combined application of arsenic trioxide and lithium chloride augments viability reduction and apoptosis induction in human rhabdomyosarcoma cell lines.
Target and Pathway
Target(s) Glycogen synthase kinase-3 alpha (GSK-3A)  Molecule Info  [3]
NetPath Pathway TGF_beta_Receptor Signaling Pathway Click to Show/Hide
Panther Pathway Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway Click to Show/Hide
2 Insulin/IGF pathway-protein kinase B signaling cascade
3 PDGF signaling pathway
4 Ras Pathway
Pathway Interaction Database Degradation of beta catenin Click to Show/Hide
2 Canonical Wnt signaling pathway
3 FOXM1 transcription factor network
4 Class I PI3K signaling events mediated by Akt
Reactome AKT phosphorylates targets in the cytosol Click to Show/Hide
2 XBP1(S) activates chaperone genes
3 Constitutive Signaling by AKT1 E17K in Cancer
References
Reference 1 Lithium chloride inhibits cell survival, overcomes drug resistance, and triggers apoptosis in multiple myeloma via activation of the Wnt/Beta-catenin pathway. Am J Transl Res. 2018 Aug 15;10(8):2610-2618.
Reference 2 Combined application of arsenic trioxide and lithium chloride augments viability reduction and apoptosis induction in human rhabdomyosarcoma cell lines. PLoS One. 2017 Jun 2;12(6):e0178857.
Reference 3 Glycogen synthase kinase 3 beta (GSK-3 beta) as a therapeutic target in neuroAIDS. J Neuroimmune Pharmacol. 2007 Mar;2(1):93-6.
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
Cite NPCDR
Visitor Map
Correspondence

X. N. Sun, Y. T. Zhang, Y. Zhou, X. C. Lian, L. L. Yan, T. Pan, T. Jin, H. Xie, Z. M. Liang, W. Q. Qiu, J. X. Wang, Z. R. Li, F. Zhu*, X. B. Sui*. NPCDR: natural product-based drug combination and its disease-specific molecular regulation. Nucleic Acids Research. 50(D1): 1324-1333 (2020). PMID: 34664659

Prof. Feng ZHU  (zhufeng@zju.edu.cn)

College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China


Prof. Xinbing SUI  (hzzju@hznu.edu.cn)

School of Pharmacy and Department of Medical Oncology, the Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, China